JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Assessing platelet-lymphocyte ratio in EGFR-mutated non-small cell lung cancer patients treated with tyrosine kinase inhibitors: An analysis across TKI generations

  • 0University of Southern California Keck School of Medicine.
Research Square +

|

November 1, 2024

|

November 1, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

The platelet-lymphocyte ratio (PLR) is a useful prognostic marker for non-small cell lung cancer (NSCLC) patients treated with first or second-generation EGFR tyrosine kinase inhibitors (TKIs). Its prognostic value is less clear with osimertinib treatment.

Area Of Science

  • Oncology
  • Medical Laboratory Science

Background

  • The prognostic utility of laboratory markers, such as the platelet-lymphocyte ratio (PLR), in non-small cell lung cancer (NSCLC) patients with EGFR mutations treated with tyrosine kinase inhibitors (TKIs) requires further investigation.
  • The specific role of PLR in patients treated with osimertinib, a third-generation EGFR TKI, remains undetermined.

Purpose Of The Study

  • To evaluate the prognostic significance of the platelet-lymphocyte ratio (PLR) in patients with EGFR-mutated NSCLC treated with different generations of TKIs.
  • To compare the changes in laboratory markers, including PLR, between patients treated with first/second-generation TKIs and those treated with osimertinib.

Main Methods

  • A retrospective analysis of 151 patients with EGFR-mutated NSCLC treated with EGFR TKIs.
  • Progression-free survival (PFS) was analyzed using Kaplan-Meier curves stratified by PLR.
  • Changes in laboratory markers were analyzed using Mann-Whitney tests and Cox Hazard Regression for multivariate analysis.

Main Results

  • Patients treated with first or second-generation TKIs with a PLR ≥ 180 had significantly shorter median PFS (10.5 months) compared to those with PLR < 180 (16.6 months, p = 0.0163).
  • Median PFS was comparable between patients treated with osimertinib, irrespective of their PLR.
  • Osimertinib treatment led to significant decreases in absolute lymphocyte count and platelets compared to first/second-generation TKIs.

Conclusions

  • The prognostic value of PLR is more pronounced in patients treated with first or second-generation EGFR TKIs than with osimertinib.
  • Third-generation EGFR TKIs like osimertinib may offer improved efficacy, potentially overcoming the negative prognostic implications of elevated PLR.
  • Observed changes in peripheral cell counts suggest TKI generation-dependent alterations in the tumor microenvironment.